[Prostaglandin analogues in glaucoma treatment]

Area of Science:

• Ophthalmology
• Glaucoma Research
• Pharmacology

Background:

• Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness.
• Effective management of intraocular pressure (IOP) is crucial for preventing glaucomatous optic neuropathy.
• Latanoprost is a prostaglandin analog commonly used for IOP reduction.

Purpose of the Study:

• To evaluate the efficacy and safety of Prolatan (latanoprost 0.005%) compared to Xalatan (latanoprost 0.005%) in treating POAG.
• To assess the impact of Prolatan on intraocular pressure and optic disc morphology.

Main Methods:

• A randomized controlled trial involving 35 POAG patients (41 eyes) aged 55-72.
• Patients were assigned to receive either Prolatan or Xalatan once daily for 3 months.
• Intraocular pressure, visual field indices (MD, PSD), and optic disc parameters (OCT) were analyzed.

Main Results:

• Prolatan demonstrated significant IOP reduction (average 28.6%) comparable to Xalatan.
• Both groups showed statistically reliable improvements in visual field (MD, PSD) and optic disc parameters (cup volume/area, rim area).
• Prolatan was well-tolerated, with no reported burning, discomfort, or foreign body sensation.

Conclusions:

• Prolatan exhibits high antihypertensive effectiveness in POAG treatment.
• Observed improvements in optic disc morphometry suggest potential neuroprotective effects.
• Prolatan's favorable tolerability profile supports its recommendation as a first-line glaucoma therapy.